PBMs, insurers restrict Ozempic, Wegovy, weight loss drug access
Payers have taken a cautious approach to handling rising demand for the pricey new class of drugs known as glucagon-like peptide agnostics, or GLP-1s.
United States Antonio Ciaccia Novo Nordisk Wegovy Tim Norfleet Unitedhealth Group Optumrx Coverage Database At Tufts Medical Center
Source: modernhealthcare.com